查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010044

抗生素市场：2026-2032年全球市场预测（依产品类型、给药途径、类型、抗菌频谱、应用及通路划分）

Antibiotics Market by Product Type, Route Of Administration, Type, Spectrum, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗生素市值将达到 489.4 亿美元，到 2026 年将成长至 519.5 亿美元，到 2032 年将达到 792.6 亿美元，复合年增长率为 7.13%。

主要市场统计数据
基准年 2025 489.4亿美元
预计年份：2026年 519.5亿美元
预测年份 2032 792.6亿美元
复合年增长率 (%) 7.13%

简明扼要地介绍全球抗生素市场趋势，阐明临床需求、监管变化、抗生素抗药性压力以及供应链的复杂性。

全球抗生素市场正处于一个转折点，临床需求、监管变化和供应链重组在此交汇融合。人们对抗菌素抗药性的认识不断提高，加上抗菌药物管理政策的不断完善和对生产品质监管的日益严格，已显着改变了医院、门诊诊所和兽医领域的需求模式。同时，技术驱动的分销、门诊治疗的扩展以及给药途径偏好的改变，也正在影响筹资策略和处方集决策。

管理现代化、监管加强、诊断技术创新和供应链韧性如何重塑整个抗生素产业的研发、生产和商业模式。

近年来，变革性的变化重新分配了竞争优势，改变了抗生素的研发、生产和分销方式。其中一个主要驱动因素是基于改进的诊断技术和监测手段而加强的抗菌药物管理。这种对维持治疗效用的重视改变了处方行为，并催生了对具有清晰抗菌频谱和更佳安全性的药物的需求。除了在临床实践中合理使用外，监管机构正在实施更严格的检查和品质标准，促使生产商加强投入以加强合规性，并重新评估与契约製造（CMO）的关係。

对关税波动对抗生素价值链供应链结构、采购韧性和製造策略的影响进行系统性评估。

关税的征收及相关贸易政策调整暴露了活性药物成分和成品抗生素长期供应链中的许多脆弱性。面对关税带来的成本压力，跨国製造商和经销商正在重新评估筹资策略，许多企业正在探索利用区域生产基地和多元化的供应商组合来缓解单一来源供应链造成的衝击。在某些情况下，製造商正在承担额外成本以维持供货管道和合约关係，而其他公司则在调整定价和分销协议，以维持利润率和供应的连续性。

为了明确每种产品在路线、来源、分销管道、应用和抗菌频谱的细微差别，从而有助于有针对性的开发、商业化和供应决策。

细分市场分析揭示了每种产品类别、给药途径、製剂来源、分销管道、适应症和抗菌频谱特征的不同机会和营运重点。产品类型包括Aminoglycosides、β-内酰胺类（包括单环胺基类酰胺类和青霉素类等亚类）、大环内酯类、磺胺类药物和四环霉素，每种药物都有其独特的抗药性考虑、治疗定位和生命週期策略。给药途径包括口服、注射和局部用药，这些因素会影响临床诱导模式、生产复杂性和分销物流。

识别重点地区独特的监管、采购和临床部署模式，以指导差异化的市场进入和供应策略。

区域趋势差异显着，反映出法律规范、医疗服务模式和采购惯例的差异，这些差异带来了独特的策略挑战。在美洲，医院抗菌药物管理计画和整合医疗系统中的采购越来越受到重视，这些系统优先考虑品质、处方集相容性和疗效评估。在这种环境下，能够提供强而有力的临床证据、可靠的低温运输和配送体系，并能快速回应医院竞标週期的供应商备受青睐。

製造商、经销商和创新者如何协调生产品质、监管灵活性和临床参与，以确保抗生素的可及性并促进永续的抗生素产品组合？

抗生素生态系统中的主要企业正在调整其优先事项，以平衡其管理责任、商业性永续性和业务永续营运。成熟的製药公司正在投资升级生产设施、完善品质保证系统并建立策略伙伴关係，以确保传统产品和差异化产品的供应更加可靠。非专利药生产商则专注于成本效益高的製程和製剂创新，以支持门诊治疗模式，促进从注射剂到口服药物的转变，并提供缓释製剂选择。

采取切实可行的策略行动，增强製造韧性、管理协调、供应多元化和证据生成，以实现可持续的商业性和临床成功。

行业领导企业应优先考虑能够降低业务风险并增强其临床和商业性地位的综合方法。首先，应投资于生产柔软性和品质改进，以确保区域供应的连续性，并能快速回应需求波动，同时确保跨辖区监管合规。这种基础性方法能够降低政策变革带来的衝击，并维持医疗保健采购方的信任。

透过结合二手文献、监管指南和专家一手检验，严格的证据整合可提供可操作的供应链、临床和商业性见解。

本研究途径结合了系统性的二手资料研究和有针对性的原始检验，以建立可靠的证据基础。二级资讯来源包括同行评审的临床文献、监管指导文件、药典标准以及公开的采购和竞标信息，涵盖了政策趋势、临床指南和品质预期。为了补充这些资料，研究人员还对临床医生、处方集管理人员、采购经理、生产品质专家和法规事务专业人员进行了访谈，以了解当前的营运实际情况和策略重点。

整合策略挑战，以平衡抗菌生态系统中的管理、监管合规、供应弹性和商业性永续性。

这些分析表明，抗生素产业将继续受到临床管理、更严格的监管和供应链韧性三者交互作用的影响。积极将生产品质与管理原则结合、投资于基于诊断的诊疗路径并实现相关人员多元化的利益相关者，将更有能力应对政策变化和日益复杂的采购流程。同时，优先考虑临床价值、稳定供应和与医疗系统伙伴关係的商业化策略，将有助于实现永续的药物取得和可靠性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗生素市场：依产品类型划分

  • Aminoglycosides
  • β-内酰胺
    • 单环胺基类抗生素
    • 青霉素
  • 大环内酯类
  • 磺胺类药物
  • 四环霉素

第九章：抗生素市场：依给药途径划分

  • 口服
  • 肠外
  • 外用

第十章：抗生素市场：依类型划分

  • 自然的
  • 合成

第十一章：抗生素市场：依作用频谱

  • 频谱
  • 窄频谱

第十二章 抗生素市场：依应用领域划分

  • 人类
  • 兽用

第十三章：抗生素市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 抗生素市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：抗生素市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 抗生素市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国抗生素市场

第十八章 中国抗生素市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc
  • Astellas Pharma Inc
  • Astra Zeneca plc
  • Aurobindo Pharma Ltd
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Ltd
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Glaxo Smith Kline plc
  • Johnson & Johnson Services Inc
  • Lupin Limited
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Ltd
Product Code: MRR-434CCDA0512F

The Antibiotics Market was valued at USD 48.94 billion in 2025 and is projected to grow to USD 51.95 billion in 2026, with a CAGR of 7.13%, reaching USD 79.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.94 billion
Estimated Year [2026] USD 51.95 billion
Forecast Year [2032] USD 79.26 billion
CAGR (%) 7.13%

A concise primer on global antibiotics dynamics clarifying drivers of clinical demand regulatory shifts resistance pressures and supply chain complexities

The global antibiotics landscape is at an inflection point defined by the convergence of clinical need, regulatory recalibration, and supply chain restructuring. Increasing awareness of antimicrobial resistance, coupled with evolving stewardship policies and heightened scrutiny of manufacturing quality, has reshaped demand patterns across hospitals, outpatient settings, and veterinary practice. At the same time, technology-enabled distribution, expanded outpatient therapeutics, and shifts in route-of-administration preference are influencing procurement strategies and formulary decisions.

Clinicians and procurement leaders now balance efficacy, resistance profiles, and access considerations while navigating a more complex supplier ecosystem. Pharmaceutical manufacturers face pressure to optimize production quality, comply with stricter regulatory expectations, and invest selectively in antibiotic R&D that leverages novel modalities or extends lifecycle value through differentiated formulations. The intersection of these forces requires stakeholders to adopt integrated approaches that address clinical, commercial, and operational dimensions concurrently.

This introduction frames the subsequent analysis by situating current dynamics within the broader context of patient safety, regulatory vigilance, and economic constraints, ensuring that readers can interpret subsequent sections through a lens of pragmatic risk management and opportunity identification.

How stewardship modernization regulatory tightening diagnostics innovation and supply chain resilience are reshaping development production and commercial models across the antibiotics landscape

Over recent years, transformative shifts have redistributed competitive advantage and altered how antibiotics are developed, produced, and distributed. A primary driver has been intensified antimicrobial stewardship informed by improved diagnostics and surveillance; this focus on preserving therapeutic utility has changed prescribing behavior and generated demand for agents with well-defined spectrums and strong safety profiles. Parallel to clinical stewardship, regulatory bodies have introduced more exacting inspections and quality expectations, prompting manufacturers to invest in compliance upgrades and to reconsider contract manufacturing relationships.

Technological advances in diagnostics are shortening the time to targeted therapy, which in turn elevates interest in narrow-spectrum agents when appropriate and accelerates adoption of parenteral-to-oral switch strategies that strengthen outpatient treatment pathways. Manufacturing resilience has become a strategic priority, with onshoring and regional diversification emerging as responses to geopolitical risk and supply disruptions. These shifts have also encouraged new commercial models, including value-based contracting and partnership structures between innovators and generic producers that extend product lifecycles while managing cost pressures.

Taken together, these trends signal a market environment that rewards operational excellence, agility in clinical engagement, and investment in differentiated formulations that align with contemporary stewardship and care-delivery paradigms.

Assessing the systemic implications of tariff shifts on supply chain configuration procurement resilience and manufacturing strategies within the antibiotics value chain

The imposition of tariffs and related trade policy adjustments has exposed vulnerabilities across long-established supply chains for active pharmaceutical ingredients and finished antibiotics. Tariff-driven cost pressures have prompted multinational manufacturers and distributors to reassess sourcing strategies, with many exploring regional production nodes and diversified supplier portfolios to mitigate exposure to single-source disruptions. In some cases, manufacturers have absorbed incremental costs to preserve access and contractual relationships, while others have restructured pricing and distribution agreements to maintain margins and continuity of supply.

The cumulative impact extends beyond unit costs to affect inventory strategies and lead times, compelling procurement teams to enlarge safety stocks or to seek alternative routes of administration that reduce dependence on constrained product lines. Contract manufacturers and API suppliers have experienced shifts in order patterns, as clients weigh the trade-offs between cost, quality, and geopolitical risk. Regulatory compliance considerations remain central, since any shift in production location or supplier requires careful validation to ensure product integrity and uninterrupted regulatory approvals.

Overall, tariff-related dynamics have accelerated strategic realignment across the value chain, reinforcing the importance of supply chain transparency, dual sourcing where feasible, and investment in manufacturing flexibility to sustain access and therapeutic continuity amid ongoing policy uncertainty.

Clarifying nuanced product route origin channel application and spectrum distinctions to inform targeted development commercialization and supply decisions

Segmentation analysis reveals differentiated opportunities and operational priorities across product classes, routes of administration, formulation origins, distribution channels, applications, and spectrum characteristics. Product type distinctions include Aminoglycosides, Beta Lactams with subcategories such as Monobactams and Penicillins, Macrolides, Sulfonamides, and Tetracyclines, each presenting unique resistance considerations, therapeutic niches, and lifecycle strategies. Route of administration considerations span oral, parenteral, and topical therapies, which influence clinical adoption patterns, manufacturing complexity, and channel logistics.

The dichotomy between natural and synthetic types highlights divergent R&D trajectories and regulatory expectations, where natural derivatives may demand distinct sourcing and quality controls while synthetic molecules can offer scalable manufacturing advantages. Distribution channels encompass hospital pharmacy, online pharmacy, and retail pharmacy, each with different procurement cycles, inventory management practices, and stakeholder touchpoints that affect market access strategies. Application segmentation across human and veterinary uses introduces different regulatory frameworks, dosing paradigms, and stewardship imperatives that shape product positioning.

Finally, spectrum classification into broad-spectrum and narrow-spectrum agents affects formulary placement, diagnostic dependency, and stewardship alignment. Integrating these segmentation lenses provides actionable clarity for product development prioritization, commercialization tactics, and supply chain design to meet the nuanced demands of diverse clinical and commercial settings.

Delineating distinct regional regulatory procurement and clinical adoption patterns across major territories to guide differentiated market entry and supply strategies

Regional dynamics are materially different and reflect variations in regulatory frameworks, healthcare delivery models, and procurement practices which create distinct strategic imperatives. In the Americas, there is heightened emphasis on hospital stewardship programs and integrated health-system procurement that prioritizes quality, formulary alignment, and outcome measurement. This environment rewards suppliers that can demonstrate robust clinical evidence, cold-chain and distribution reliability, and responsiveness to hospital tender cycles.

In Europe, Middle East & Africa, heterogeneity across national regulatory capacities and reimbursement structures creates diverse pathways to adoption. Some markets emphasize generics and cost containment while others prioritize access and quality assurance, encouraging suppliers to adopt flexible pricing models and to invest in local regulatory partnerships. The region also exhibits active antimicrobial surveillance initiatives that influence product selection and stewardship deployment.

Asia-Pacific encompasses mature markets with sophisticated hospital networks alongside emerging markets where access and affordability remain central. Rapid urbanization and expanding outpatient care are shifting consumption patterns toward oral and simplified parenteral therapies, while several countries are strengthening regulatory oversight and local manufacturing capabilities. Across all regions, tailored market entry strategies that reflect local clinical guidelines, procurement frameworks, and supply chain realities produce the best outcomes for sustained access and commercial viability.

How manufacturers distributors and innovators are aligning manufacturing quality regulatory agility and clinical engagement to protect access and drive sustainable antibiotic portfolios

Leading companies across the antibiotics ecosystem are recalibrating priorities to balance stewardship obligations with commercial sustainability and operational resilience. Established pharmaceutical manufacturers are investing in manufacturing upgrades, quality assurance systems, and strategic partnerships that enable more reliable supply of both legacy and differentiated products. Generic producers are focusing on cost-effective processes and formulation innovations that facilitate parenteral-to-oral switches and extended-release options to support outpatient care models.

Smaller innovators and specialty firms are pursuing niche differentiation through novel delivery formats, targeted-spectrum agents, and companion diagnostics that enhance clinical appropriateness and support premium positioning. Across the value chain, strategic alliances between innovators, contract manufacturers, and distribution partners are becoming more common as a way to share risk and accelerate access. Additionally, companies are increasingly transparent about stewardship commitments and clinical evidence generation, recognizing that payers and health systems now evaluate antibiotics within broader antimicrobial resistance strategies.

Corporate strategies that combine manufacturing excellence, regulatory agility, and credible clinical engagement tend to perform best in preserving market access and fostering long-term partnerships with healthcare providers and procurement organizations.

Practical strategic actions to enhance manufacturing resilience stewardship alignment supply diversification and evidence generation for sustained commercial and clinical success

Industry leaders should prioritize integrated actions that simultaneously reduce operational risk and strengthen clinical and commercial positioning. First, invest in manufacturing flexibility and quality upgrades to enable regional supply continuity and rapid response to demand shifts while ensuring regulatory compliance across jurisdictions. This foundational work reduces vulnerability to policy disruptions and protects reputation with healthcare purchasers.

Second, embed stewardship-aligned product strategies by developing and promoting diagnostics-linked prescribing pathways, and by tailoring formulations that enable safe outpatient management and reduced hospital stays. These efforts not only support public health objectives but also align product value with payer priorities. Third, diversify supplier networks and consider nearshoring where feasible to mitigate tariff and geopolitical exposures, while maintaining rigorous supplier qualification and validation processes to preserve product integrity.

Fourth, cultivate collaborative commercial models with health systems and payers that emphasize outcomes, supply reliability, and appropriate use. Finally, accelerate clinical evidence generation that demonstrates real-world impact on patient outcomes and resistance patterns, thereby strengthening formulary positioning and supporting long-term access agreements. Taken together, these steps create a defensible platform for both stewardship and business continuity.

A rigorous evidence synthesis combining secondary literature regulatory guidance and primary expert validation to deliver actionable supply chain clinical and commercial insights

The research approach combined systematic secondary research with targeted primary validation to construct a robust evidence base. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, pharmacopoeial standards, and publicly available procurement and tender information to map policy trajectories, clinical guidelines, and quality expectations. This foundation was complemented by primary interviews with clinicians, formulary managers, procurement leaders, manufacturing quality specialists, and regulatory affairs professionals to capture contemporary operational realities and strategic priorities.

Data triangulation methods were used to reconcile differences between published guidance and on-the-ground practice, with emphasis on supply chain case studies that illustrate how tariffs and regulatory shifts materially affect procurement and production decisions. Analytical frameworks focused on segmentation-driven insights, scenario analysis for supply disruption responses, and comparative regional assessments. Quality control measures included source verification, expert peer review of synthesized findings, and transparent documentation of assumptions and analytical steps to ensure reproducibility and practical relevance to decision-makers.

Synthesis of the strategic imperatives for balancing stewardship regulatory compliance supply resilience and commercial sustainability within the antibiotics ecosystem

The cumulative analysis underscores that the antibiotics sector will continue to be shaped by the interplay of clinical stewardship, regulatory rigor, and supply chain resilience. Stakeholders that proactively align manufacturing quality with stewardship principles, invest in diagnostic-enabled care pathways, and diversify sourcing will be better positioned to navigate policy shifts and procurement complexity. At the same time, commercialization strategies that emphasize clinical value, reliable supply, and partnerships with health systems will foster sustainable access and credibility.

Decisions taken now around production footprint, formulation development, and evidence generation will have long-term implications for access, cost management, and therapeutic effectiveness. Organizations that integrate clinical science, operations, and commercial strategy into a coherent roadmap will not only mitigate near-term risks but also create differentiated propositions that support appropriate antibiotic use and meet evolving healthcare priorities. The conclusion invites leaders to act deliberately and to leverage targeted intelligence when shaping investment, procurement, and clinical engagement choices.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibiotics Market, by Product Type

  • 8.1. Aminoglycosides
  • 8.2. Beta Lactams
    • 8.2.1. Monobactams
    • 8.2.2. Penicillins
  • 8.3. Macrolides
  • 8.4. Sulfonamides
  • 8.5. Tetracyclines

9. Antibiotics Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Topical

10. Antibiotics Market, by Type

  • 10.1. Natural
  • 10.2. Synthetic

11. Antibiotics Market, by Spectrum

  • 11.1. Broad Spectrum
  • 11.2. Narrow Spectrum

12. Antibiotics Market, by Application

  • 12.1. Human
  • 12.2. Veterinary

13. Antibiotics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Antibiotics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antibiotics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antibiotics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Antibiotics Market

18. China Antibiotics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AbbVie Inc
  • 19.7. Astellas Pharma Inc
  • 19.8. Astra Zeneca plc
  • 19.9. Aurobindo Pharma Ltd
  • 19.10. Bayer AG
  • 19.11. Bristol Myers Squibb Company
  • 19.12. Cipla Ltd
  • 19.13. Dr Reddy's Laboratories Ltd
  • 19.14. Eli Lilly and Company
  • 19.15. Glaxo Smith Kline plc
  • 19.16. Johnson & Johnson Services Inc
  • 19.17. Lupin Limited
  • 19.18. Merck & Co Inc
  • 19.19. Novartis AG
  • 19.20. Pfizer Inc
  • 19.21. Sanofi S A
  • 19.22. Sun Pharmaceutical Industries Ltd
  • 19.23. Teva Pharmaceutical Industries Ltd
  • 19.24. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBIOTICS MARKET SIZE, BY MONOBACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBIOTICS MARKET SIZE, BY MONOBACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBIOTICS MARKET SIZE, BY MONOBACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBIOTICS MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBIOTICS MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBIOTICS MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBIOTICS MARKET SIZE, BY BROAD SPECTRUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBIOTICS MARKET SIZE, BY BROAD SPECTRUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBIOTICS MARKET SIZE, BY BROAD SPECTRUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBIOTICS MARKET SIZE, BY NARROW SPECTRUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBIOTICS MARKET SIZE, BY NARROW SPECTRUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBIOTICS MARKET SIZE, BY NARROW SPECTRUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBIOTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBIOTICS MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBIOTICS MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBIOTICS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBIOTICS MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBIOTICS MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)